The "Cerebrospinal Fluid Sink Therapeutic Strategy" in Alzheimer's Disease-From Theory to Design of Applied Systems

被引:9
|
作者
Schreiner, Thomas Gabriel [1 ,2 ,3 ]
Menendez-Gonzalez, Manuel [4 ,5 ,6 ]
Popescu, Bogdan Ovidiu [1 ,7 ,8 ]
机构
[1] Univ Med & Pharm Carol Davila, Fac Med, Bucharest 050474, Romania
[2] Univ Med & Pharm Gr T Popa, Dept Neurol, Iasi 700115, Romania
[3] Gheorghe Asachi Tech Univ Iasi, Fac Elect Engn & Informat Technol, Dept Elect Measurements & Mat, Iasi 700050, Romania
[4] Univ Oviedo, Dept Med, Oviedo 33006, Spain
[5] Hosp Univ Cent Asturias, Dept Neurol, Oviedo 33006, Spain
[6] Inst Invest Sanitaria Principado Asturias, Oviedo 33006, Spain
[7] Colentina Clin Hosp, Neurol Dept, Bucharest 020125, Romania
[8] Victor Babes Natl Inst Pathol, Lab Cell Biol Neurosci & Expt Myol, Bucharest 050096, Romania
关键词
Alzheimer's disease; amyloid-beta; cerebrospinal fluid; therapy; implantable device; clearance; AMYLOID-BETA; MOUSE MODEL; NEPRILYSIN; CLEARANCE;
D O I
10.3390/biomedicines10071509
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is a global health problem, with incidence and prevalence considered to increase during the next decades. However, no currently available effective treatment exists despite numerous clinical trials in progress. Moreover, although many hypotheses are accepted regarding the pathophysiological mechanisms of AD onset and evolution, there are still many unknowns about the disorder. A relatively new approach, based on the amyloid-beta dynamics among different biological compartments, is currently intensely discussed, as it seems to offer a promising solution with significant therapeutic impact. Known as the "cerebrospinal-fluid-sink therapeutic strategy", part of the "three-sink therapeutic strategy", this theoretical model focuses on the dynamics of amyloid-beta among the three main liquid compartments of the human body, namely blood, cerebrospinal fluid, and the (brain) interstitial fluid. In this context, this article aims to describe in detail the abovementioned hypothesis, by reviewing in the first part the most relevant anatomical and physiological aspects of amyloid-beta dynamics. Subsequently, explored therapeutic strategies based on the clearance of amyloid-beta from the cerebrospinal fluid level are presented, additionally highlighting their limitations. Finally, the originality and novelty of this work rely on the research experience of the authors, who focus on implantable devices and their utility in AD treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in Alzheimer's disease
    Sáez-Valero, J
    Small, DH
    BRAIN RESEARCH, 2001, 889 (1-2) : 247 - 250
  • [42] Endostatin Level in Cerebrospinal Fluid of Patients with Alzheimer's Disease
    Salza, Romain
    Oudart, Jean-Baptiste
    Ramont, Laurent
    Maquart, Francois-Xavier
    Bakchine, Serge
    Thoannes, Henri
    Ricard-Blum, Sylvie
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 44 (04) : 1253 - 1261
  • [43] New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood
    Vogelgsang, Jonathan
    Wiltfang, Jens
    NERVENARZT, 2019, 90 (09): : 907 - 913
  • [44] Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer's disease
    Eddin, Ahmed Noor
    Hamsho, Khaled
    Adi, Ghaith
    Al-Rimawi, Mohammed
    Alfuwais, Mohammed
    Rab, Saleha Abdul
    Alkattan, Khaled
    Yaqinuddin, Ahmed
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [45] Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly
    Randall, Catherine
    Mosconi, Lisa
    De Leon, Mony
    Glodzik, Lidia
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2013, 18 : 1150 - 1173
  • [46] Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
    Huynh, Rose Ann
    Mohan, Chandra
    FRONTIERS IN NEUROLOGY, 2017, 8
  • [47] Pilot proteomic analysis of cerebrospinal fluid in Alzheimer's disease
    McKetney, Justin
    Panyard, Daniel J.
    Johnson, Sterling C.
    Carlsson, Cynthia M.
    Engelman, Corinne D.
    Coon, Joshua J.
    PROTEOMICS CLINICAL APPLICATIONS, 2021, 15 (2-3)
  • [48] Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?
    Zetterberg, Henrik
    Blennow, Kaj
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 33 : S361 - S369
  • [49] Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease
    White, Matthew T.
    Shaw, Leslie M.
    Xie, Sharon X.
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 51 (02) : 463 - 470
  • [50] Cerebrospinal Fluid Epinephrine in Alzheimer's Disease and Normal Aging
    Elaine R Peskind
    Rachael Elrod
    Dorcas J Dobie
    Marcella Pascualy
    Eric Petrie
    Carl Jensen
    Kayla Brodkin
    Sharon Murray
    Richard C Veith
    Murray A Raskind
    Neuropsychopharmacology, 1998, 19 : 465 - 471